MOLECULAR PHARMACOLOGY (USA) LTD. — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/bf3e9419-6ca0-4b34-9987-7baba5c713f1/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2014 | $-2.2M | 2004-07-14 – 2014-09-30 | evidence 0001221508-14-000024 |
| FY 2013 | $-2.1M | 2004-07-14 – 2014-03-31 | evidence 0001221508-14-000007 |
| FY 2012 | $-2.0M | 2004-07-14 – 2013-03-31 | evidence 0001221508-13-000008 |
| FY 2011 | $-1.8M | 2004-07-14 – 2012-03-31 | evidence 0001221508-12-000013 |
| FY 2010 | $-117.2k | 2009-07-01 – 2010-06-30 | evidence 0001221508-11-000015 |
| FY 2009 | $-94.4k | 2008-07-01 – 2009-06-30 | evidence 0001221508-14-000021 |
| FY 2008 | $62.3k | 2007-07-01 – 2008-06-30 | evidence 0001221508-14-000021 |
| FY 2006 | $-508.3k | 2005-11-01 – 2006-10-31 | evidence 0001221508-14-000021 |
| FY 2005 | $-387.7k | 2004-11-01 – 2005-10-31 | evidence 0001221508-14-000021 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
MOLECULAR PHARMACOLOGY (USA) LTD. — all facts · Operating Income